Radiopharm Theranostics Ltd (RADX) shareholders
RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF
$0.76−0.03 (-3.80%)
Close on Nov 13, 2026Market cap $8.98MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
51M
Shares held, 13F filers
Institutional holders
7
1 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lantheus Holdings, Inc. Joint filing with Lantheus Omega, LLC (17.30%), Lantheus Medical Imaging, Inc. (17.30%) | 792,958,513 | 17.30% | 13G (passive) | Jul 28, 2026 |
| Lantheus Omega, LLC Joint filing with Lantheus Medical Imaging, Inc. (20.90%), Lantheus Holdings, Inc. (20.90%) | 792,958,513 | 20.90% | 13D (active) | Nov 27, 2024 |
| Regal Partners Holdings Pty Limited Joint filing with Regal Partners Funds Management Pty Limited (9.05%), Regal Partners Limited (9.05%) | 320,694,680 | 9.05% | 13G (passive) | Dec 31, 2025 |
| Regal Funds Management Pty Limited | 172,634,988 | 7.30% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RADX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 51,000,000 | – | $670.50K | – | 0.38% |
| Hsbc Holdings PLC | 62,188 | – | $253.73K | +816 | 0.00% |
| Regal Partners Ltd | 40,138 | – | $168.18K | – | 0.01% |
| PNC Financial Services Group, Inc. | 20,000 | – | $83.80K | +4,000 | 0.00% |
| UBS Group AG | 1,507 | – | $6.31K | −1,493 | 0.00% |
| Integrated Wealth Concepts LLC | 1,310 | – | $5.49K | New | 0.00% |
| Rhumbline Advisers | 195 | – | $817 | +74 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 7 | 51M | 1 / 3 | 1 / 1 | 0M | 0M |
| Q1 2026 | 7 | 51M | 0 / 1 | 3 / 4 | 0M | 0M |
| Q4 2025 | 11 | 52M | 7 / 0 | 1 / 0 | 51M | 0M |
| Q3 2025 | 4 | 0M | 0 / 2 | 0 / 1 | 0M | 0M |
| Q2 2025 | 5 | 0M | 2 / 0 | 1 / 0 | 0M | 0M |
| Q1 2025 | 3 | 0M | 0 / 0 | 1 / 1 | 0M | 0M |
| Q4 2024 | 4 | 0M | 4 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Riccardo Canevari | Managing Director and CEO | 22,679,986 | Mar 31, 2026 |
| Dimitris Voliotis | Chief Medical Officer | – | Oct 27, 2026 |
| Aaron James Laurita | Chief Financial Officer | 26,357 | Apr 30, 2026 |
| Paul Hopper | Director | 147,721,428 | May 6, 2026 |
| Ian Lawrence Turner | Director | 9,985,292 | Apr 1, 2026 |
| Noel Donnelly | Director | – | Apr 1, 2026 |
| Hester Denise Larkin | Director | 644,247 | Mar 31, 2026 |
| Bruce Michael Goodwin | Director | – | Mar 18, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
4.5
At 0M shares a day
Change since last report
-5.3%
From 0M shares
Short volume, 20 days
54.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Radiopharm Theranostics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,000 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?